摘要
目的研究鲍曼不动杆菌对头孢哌酮/舒巴坦及多种抗生素的耐药现状,以及是否可以继续将头孢哌酮/舒巴坦作为临床针对鲍曼不动杆菌的首选经验用药,为防控医院感染提供依据。方法对2011年1月-2015年12月分离的1 558株鲍曼不动杆菌的标本进行了实验室分析;统计了鲍曼不动杆菌对头孢哌酮/舒巴坦等常用抗菌药物的耐药率。结果鲍曼不动杆菌在痰标本的检出率最高为79.6%;对常用抗生素的耐药率基本都在60%以上,而头孢哌酮/舒巴坦2011年耐药率为11.3%,2012年为12.4%,2013年为15.4%,2014年为18.4%,2015年为20.1%。结论鲍曼不动杆菌在临床上主要是由痰液标本中分离得到,常规经验用药头孢哌酮/舒巴坦近5年的耐药性也只呈现轻微的上升趋势,因此可以继续将头孢哌酮/舒巴坦作为临床的首选经验用药,但还需警惕并高度重视该菌感染及耐药监测,以减少耐药菌株的产生和播散。
Objective To investigate drug resistance of Acinetobacter baumanii（ A. baumanii） to cefoperazone/sulbactam and other antimicrobial agents,and the possibility to use cefoperazone/sulbactam as the primary drug to treat A. baumanii,so as to provide evidence for preventing nosocomial infection. Methods From January 2011 to December 2015,1 558 strains of A. baumanii were collected for laboratory analysis. Then,drug resistance rates of A. baumanii to cefoperazone/sulbactam and other antimicrobial agents were counted. Results Positive rate of A. baumanii in sputum was the highest,accounting for 79. 6%; drug resistance rates of A. baumanii to common antimicrobial agents were more than 60%,and drug resistance rates of A. baumanii to cefoperazone/sulbactam in 2011,2012,2013,2014,2015 were 11. 3%,12. 4%,15. 4%,18. 4%,20. 1%,respectively.Conclusion A. baumanii were mainly isolated from sputum,drug resistance rates of A. baumanii to cefoperazone/sulbactam were rising up in the 5 years. So,cefoperazone/sulbactam is able to be used as the primary drug to treat A. baumanii. But we should pay attention to A. baumanii and perform resistance monitor,in order to reduce production and transmission of drug- resistant strains.
作者
王盛
胡丽庆
翁幸鐾
WANG Sheng HU Li-qing WENG Xing-bei(Clinical Laboratory,the First Hospital of Ningbo, Ningbo, Zhejiang315010, China)
出处
《中国卫生检验杂志》
CAS
2016年第20期3031-3032,3037,共3页
Chinese Journal of Health Laboratory Technology
关键词
鲍曼不动杆菌
头孢哌酮/舒巴坦
耐药性分析
Acinetobacter baumanii
Cefoperazone/sulbactam
Drug resistance analysis
